17.49
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché TNXP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$17.39
Aprire:
$16.71
Volume 24 ore:
636.84K
Relative Volume:
0.40
Capitalizzazione di mercato:
$108.62M
Reddito:
-
Utile/perdita netta:
$-121.02M
Rapporto P/E:
-1.5533
EPS:
-11.26
Flusso di cassa netto:
$-114.09M
1 W Prestazione:
-34.42%
1M Prestazione:
+136.99%
6M Prestazione:
+38.81%
1 anno Prestazione:
-97.25%
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Nome
Tonix Pharmaceuticals Holding Corp
Settore
Industria
Telefono
212-980-9155
Indirizzo
26 MAIN STREET, SUITE 101, CHATHAM, NY
Confronta TNXP con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
TNXP
Tonix Pharmaceuticals Holding Corp
|
17.49 | 108.62M | 0 | -121.02M | -114.09M | -11.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2022-04-18 | Iniziato | Noble Capital Markets | Outperform |
2019-04-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
2017-08-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
2016-09-07 | Downgrade | ROTH Capital | Buy → Neutral |
2016-02-17 | Reiterato | Oppenheimer | Outperform |
2015-11-04 | Iniziato | Cantor Fitzgerald | Buy |
2015-06-12 | Iniziato | Oppenheimer | Outperform |
2015-02-17 | Reiterato | ROTH Capital | Buy |
2014-09-29 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie
Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference - GlobeNewswire
Tonix Pharma stock rises following TONIX ONE launch - Investing.com Australia
Tonix Pharma stock rises following TONIX ONE launch By Investing.com - Investing.com UK
Tonix Pharmaceuticals launches migraine management platform - Investing.com
Tonix Pharmaceuticals launches migraine management platform By Investing.com - Investing.com Canada
Tonix Pharmaceuticals Launches TONIX ONE™, a - GlobeNewswire
Game-Changing Digital Platform Transforms How Patients Track and Treat Migraines - Stock Titan
Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year - ACCESS Newswire
Revolutionary Non-Opioid Pain Drug Could Transform Fibromyalgia Treatment by 2025 - Stock Titan
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. - Bluefield Daily Telegraph
(TNXP) Long Term Investment Analysis - Stock Traders Daily
Tonix Pharmaceuticals Announces Presentation at the - GlobeNewswire
Fast-Tracked Fibromyalgia Treatment: Tonix Showcases Breakthrough Pain Drug Data Before FDA Decision - StockTitan
2 Stocks Riding the Biotech Surge With Major Catalysts Ahead - Investing.com
Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years - Seeking Alpha
Noble Capital maintains Outperform on Tonix Pharma, $70 target By Investing.com - Investing.com South Africa
Noble Capital maintains Outperform on Tonix Pharma, $70 target - Investing.com
Tonix Pharmaceuticals: FDA AdCom News Positive, But Making Bull Case Is Problematic (TNXP) - Seeking Alpha
Pharma Frenzy: Volatility Ignites Biotech Sector - Benzinga
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
Tonix advances fibromyalgia drug, eyes Q4 2025 launch By Investing.com - Investing.com Australia
Tonix Pharmaceuticals Says US FDA Will Not Require Committee Meeting to Discuss NDA for Fibromyalgia Treatment; Shares Up - MarketScreener
Tonix advances fibromyalgia drug, eyes Q4 2025 launch - Investing.com India
Tonix Pharmaceuticals Says US FDA Will Not Require Committee Meeting to Discuss NDA for Fibromyalgia Treatment - Marketscreener.com
Tonix Pharmaceuticals stock soars on FDA update By Investing.com - Investing.com Australia
Tonix Pharmaceuticals stock soars on FDA update - Investing.com
Tonix Pharma’s TNX-102 SL Advances in FDA Process - TipRanks
Tonix Pharmaceuticals Announces that FDA Will Not Require - GlobeNewswire
First New Fibromyalgia Treatment in 15 Years Advances: FDA Expedites TNX-102 SL Review - Stock Titan
Tonix Pharmaceuticals Stock Dives After Q4 Earnings Miss, But Retail’s Feeling Bullish - MSN
As Mpox Cases Spread Around the World, Tonix Pharmaceuticals’ Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread - BioSpace
New Single-Dose Mpox Vaccine Outperforms Existing Options as Cases Surge Worldwide - StockTitan
Tonix Pharma stock drops after Q4 revenue miss (TNXP:NASDAQ) - Seeking Alpha
Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Why StoneCo Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals Reports 2024 Financial Results and Pipeline Progress - TipRanks
Tonix Pharmaceuticals stock tumbles on earnings miss - Investing.com India
Tonix Pharma earnings missed by $5.86, revenue fell short of estimates - Investing.com
Tonix Pharmaceuticals stock tumbles on earnings miss By Investing.com - Investing.com Australia
Tonix Pharmaceuticals Holding Corp. SEC 10-K Report - TradingView
Tonix Pharmaceuticals 8-K Filing Analysis - TradingView
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights - GlobeNewswire
Tonix Secures Path to First New Fibromyalgia Drug in 15 Years with $98.8M War Chest - StockTitan
Learn to Evaluate (TNXP) using the Charts - Stock Traders Daily
* Tonix pharmaceuticals announces 1-for-10 reverse stock split - Reuters
Tonix Pharmaceuticals secures MCDC grant to advance next-gen Mpox & Smallpox vaccine development - Proactive Investors USA
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - The Manila Times
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025 - GlobeNewswire
Major FDA Decision Looms: Tonix's Revolutionary Fibromyalgia Treatment Could End 15-Year Innovation Drought - StockTitan
Tonix’s TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target - BioSpace
Tonix Pharmaceuticals Holding Corp Azioni (TNXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):